Phase 2, open-label study of ITM-014 in patients with neuroendocrine tumour(Extension Study)
Latest Information Update: 07 Dec 2021
At a glance
- Drugs Lanreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms Study 002
- Sponsors Teijin Pharma
- 25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium
- 07 Jun 2016 New trial record